{"filing":{"accession_number":"0001213900-26-066782","cik":"0001788028","ticker":"JSPRW","company_name":"Jasper Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"ea0294010-8k_jasper.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026066782/ea0294010-8k_jasper.htm"},"events":[{"id":4365,"run_id":3816,"accession_number":"0001213900-26-066782","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Jasper Therapeutics received written notice from Nasdaq on June 3, 2026, that its voting common stock bid price closed below the $1.00 minimum requirement for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The company has been granted an initial 180-day compliance period (until November 30, 2026) to regain compliance, with potential for a second 180-day period if certain conditions are met. This is a classic delisting risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued public trading status.","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-06-09","items":[{"id":5493,"accession_number":"0001213900-26-066782","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Jasper Therapeutics received written notice from Nasdaq on June 3, 2026, that its voting common stock bid price closed below the $1.00 minimum requirement for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The company has been granted an initial 180-day compliance period (until November 30, 2026) to regain compliance, with potential for a second 180-day period if certain conditions are met. This is a classic delisting risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued public trading status.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:07:24.986958+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5493,"accession_number":"0001213900-26-066782","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Jasper Therapeutics received written notice from Nasdaq on June 3, 2026, that its voting common stock bid price closed below the $1.00 minimum requirement for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The company has been granted an initial 180-day compliance period (until November 30, 2026) to regain compliance, with potential for a second 180-day period if certain conditions are met. This is a classic delisting risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued public trading status.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:07:24.986958+00:00","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-06-09"}]}